ANNUAL DECLARATION OF INTERESTS (ADoI)

(Please note that high quality of scientific expertise is by nature based on prior experience and that therefore having an interest does not necessarily mean having a conflict of interest)

Name: WRIGHT, Matthew
Title: Prof
Profession: Biochemistry

Current EFSA involvements: Member-ANS Panel 2011-2014 (ANS), Member-Emerging Risks (Standing Working Group) (EMRISK), Vice-Chair-WG 'A' Food additives and nutrient sources 2011-2014 (ANS), Member-WG on Aspartame (ANS), Member-WG on Toxicology (ANS)

Nature of Activities	Period	Organisation	Subject matter
I. Economic interest			NO INTEREST
II. Member of a management body or equivalent structure			NO INTEREST

ANS = Food Additives and Nutrient Sources Added to Food; EMRISK = Emerging risks

III. Member of a scientific advisory body	07/2011 - 09/2012	-Name: EFSA, European Food Safety Authority, Italy, Parma	Member - WG 'A' Food additives and nutrient sources 2011-2014 (ANS). The European Food Safety Authority (EFSA) is the keystone of European Union (EU) risk assessment regarding food and feed safety. In close collaboration with national authorities and in open consultation with its stakeholders, EFSA provides independent scientific advice and clear communication on existing and emerging risks. 1) the remit of the managing structure: The work of the Panel on Food Additives and Nutrient Sources added to Food (ANS) concerns food additives, nutrient sources added to food (e.g. sources of vitamins and minerals) and other substances deliberately added to food, including for purposes other than technological ones, e.g. with functional properties, but excluding flavourings and enzymes. 2) the nature of the entity and organisation and what it does: The ANS Panel carries out risk assessments in order to produce scientific opinions and advice for risk managers. The Panels' risk assessment work is based on reviewing scientific information and data usually submitted by applicants or by interested parties, in order to evaluate the safety of use of the substances, processing aids or processes in question. This provides a sound foundation for European policies and legislation, and supports risk managers in taking effective and timely decisions.
	12/2011 - 08/2012	-Name: EFSA, European Food Safety Authority, Italy, Parma	Member - WG 'Guidance on Food additives' (ANS). The European Food Safety Authority (EFSA) is the keystone of European Union (EU) risk assessment regarding food and feed safety. In close collaboration with national authorities and in open consultation with its stakeholders, EFSA provides independent scientific advice and clear communication on existing and emerging risks. 1) the remit of the managing structure: The work of the Panel on Food Additives and Nutrient Sources added to Food (ANS) concerns food additives, nutrient sources added to food (e.g. sources of vitamins and minerals) and other substances deliberately added to food, including for purposes other than technological ones, e.g. with functional properties, but excluding flavourings and enzymes. 2) the nature of the entity and organisation and what it does: The ANS Panel carries out risk assessments in order to produce scientific opinions and advice for risk managers. The Panels' risk assessment work is based on reviewing scientific information and data usually submitted by applicants or by interested parties, in order to evaluate the safety of use of the substances, processing aids or processes in question. This provides a sound foundation for European policies and legislation, and supports risk managers in taking effective and timely decisions.

IV. Employment	10/2006 - now	-Name: Newcastle University	Main employment - Teaching/research in Toxicology. On moving to Newcastle, my research has involved generating a transgenic PXR knockout SJL/J mouse line (and archived by the Medical Research Council) on which we can examine the effects of the PXR in inflammatory diseases such as primary biliary cirrhosis. A major research interest has been the development of human hepatocytes for toxicological research (toxicology and drug metabolism studies). Work with a plastic pancreatic progenitor cell has been ongoing with regard to its ability to differentiate into hepatocytes. The work has been the first to show high (hepatocyte) levels of functional cytochrome P450 expression in these cells. We have extended these studies to demonstrate for the first time that the Wnt and SGK1 signalling pathways are involved in this process. The potential for this phenomenon to occur as a pathophysiological response to elevated glucocorticoid has been demonstrated using a transgenic mouse model of Cushing's disease and by screening patients who are maintained long term on therapeutic levels of glucocorticoid. This work has involved collaborating with a number of colleagues throughout the University including Mr Steve White (Surgeon), Prof Jim Shaw (Pancreas), Prof Paul Flecknell (role of adrenals in animal studies) and Prof Alastair Burt (Pathology) and exemplifies my "team" / collaborative approach to research. Other collaborations include those of a more classical toxicological nature which will begin to show results in a year or two. These include investigations into xenooestrogens and cholestatic liver disease (Prof Peter Blain and Prof Dave Jones) and drug induced liver injury (Prof Ann Daly). These contributions and others to the liver research field are recognised both nationally and internationally. External esteem indicators include membership of the editorial boards of international journals and invitations to speak at national and international meetings. I have significant experience of developing and running undergraduate courses. As a relatively new member of Newcastle University, I make contributions to Pharmacology and Toxicology teaching at undergraduate level. I teach on both the PED201 and PED3011 courses. I also make a significant contributions to postgraduate teaching through provision of taught material (CMS8015, MMB8008 and the new NC3Rs MRes course), through the development of a new MRes course in Toxicology and through supervision of research students. I have supervised 9 PhD students to date, acting as the principal or sole supervisor for 7 of these. All students to date have submitted on time. I am currently supervising 6 PhD students at Newcastle, 5 as principal or sole supervisor. I also undertake third strand activity through the continued development of a recombinant human antibody protein to a surface protein on fibrogenic cells. Through research agreements with a pharmaceutical company that has licensed this antibody, academic research is continuing to be funded.
V. Ad hoc or occasional consultancy			NO INTEREST
VI. Research funding	08/2012 - now	-Name: Medical Research Council	ITTP studentship. Investigating the Adverse Effects of Novel Tumour-specific IAP Antagonists.

	08/2012 - now	-Name: Medical Research Council	Derivation of Human Hepatocytes from Pancreatic Progenitor Cells and their use in a Novel Antioxidant Screening Platform
	08/2012 - now	-Name: Medical Research Council	Targeting MEK and VEGF inhibition to prevent melanoma metastasis and angiogenesis.
	07/2012 - now	-Name: Wellcome Trust	Production of functional hepatocytes from a progenitor cell line in vitro.
	10/2011 - now	-Name: European Commission	Information and Communication Technology (ICT)-enabled, cellular artificial liver system incorporating personalised patient management and support (D-LIVER).
	10/2011 - now	-Name: The National Centre for the Replacement, Refinement and Reduction of Animals in Research (NC3Rs)	Applying the 3 R's to Liver Fibrosis Research.
	10/2010 - now	-Name: MRC (Case studentship with AstraZeneca)	Determination of mechanisms of flucloxacillin induced liver injury; translation to refining risk assessment screening.
	10/2010 - now	-Name: Medical Research Council	Myofibroblasts and their regulation of hepatic stem/progenitor cell function after injury
	10/2009 - now	-Name: Pfizer	Fund PhD studentships - Myofibroblasts and stem/progenitor cell function.
	10/2008 - 09/2011	-Name: British Toxicology Society, UK, Macclefield	Academic research indicating sunset yellow was a human estrogen receptor activator.
VII. Intellectual property rights	10/2007 - now	-Name: Pfizer	Previous employer (University of Aberdeen) licensed C1-3 antibody technology to Pfizer. Currently Pfizer funding project - Myofibroblasts and imaging fibrosis. I could receive personal financial benefit if the antibody is developed for use as a therapeutic in man.
VIII. Other membership or affiliation	12/2000 - now	-Name: British Toxicology Society	Member of Executive Committe
	10/1992 - now	-Name: Biochemical Society	Member
IX. Other relevant interest			NO INTEREST
X. Interests of close family members			NO INTEREST

I hereby declare that I have read both the Guidance Document on Declarations of Interests and the Procedure for identifying and handling potential conflict of interests and that the above Declaration of Interests is complete.

Date: 11/03/2013 Signature: SIGNED